Hormonal
Weight loss is associated with a statistically nonsignificant decrease in diabetes risk, suggesting that while weight gain is a strong predictor, weight loss may not immediately reverse risk to baseline levels in this cohort.
While preventing weight gain is crucial, do not assume that losing weight will instantly eliminate your diabetes risk if you have a history of obesity. The study suggests weight loss did not significantly reduce risk in this specific analysis, possibly due to the duration of prior obesity.
Among the entire cohort, weight gain was associated with increased risk for diabetes, whereas weight loss was associated with a statistically nonsignificant, decreased risk of diabetes.
Why this rating
Same cohort limitations as N1; the lack of significance may be due to sample size in weight loss categories or misclassification.
Source
Weight Change and Diabetes Incidence: Findings from a National Cohort of US Adults
E. S. Ford et al. · American Journal of Epidemiology · 1997
DOI 10.1093/oxfordjournals.aje.a009256
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →